Robbins, PF, Kassim, SH, Tran, TL, Crystal, JS, Morgan, RA, Feldman, SA, Yang, JC, Dudly, ME, Wunderlich, JR, Sherry, RM, Kammula, US, Hughes, MS, Restifo, NP, Raffeld, M, Lee, CR, Li, YF, El-Gamil, M and Rosenberg, SA (2014) A pilot trial using lymphocytes genetically engineered with an NY-ESO-1-reactive T cell receptor: Long term follow up and correlates with response. Clinical Cancer Research.

Abstract

Purpose:Although adoptive cell therapy can be highly effective for the treatment of patients with melanoma, the application of this approach to the treatment of other solid tumors has been limited. The observation that the cancer germline (CG) antigen NY-ESO-1 is expressed in 70-80% and in approximately 25% of patients with synovial cell sarcoma and melanoma, respectively, prompted us to perform this first-in-man clinical trial employing the adoptive transfer of autologous PBMC that were retrovirally transduced with an NY-ESO-1 reactive TCR to heavily pretreated patients bearing these metastatic cancers. Experimental Design:HLA-*0201 patients with metastatic synovial cell sarcoma or melanoma refractory to standard treatments and whose cancers expressed NY-ESO-1 received autologous TCR-transduced T cells following a lymphodepleting preparative chemotherapy. Response rates using Response Evaluation Criteria in Solid Tumors (RECIST), as well as immunologic correlates of response, are presented in this report. Results:Eleven of 18 patients with NY-ESO-1+ synovial cell sarcomas (61%) and 11 of 20 patients with NY-ESO-1 positive melanomas (55%) who received autologous T cells transduced with an NY-ESO-1-reactive TCR demonstrated objective clinical responses. The estimated overall three and five year survival rates for patients with synovial cell sarcoma were 38 and 14%, respectively, while the corresponding estimated survival rates for patients with melanoma were both 33%. Conclusions:

Item Type:	Article
Additional Information:	NIBR author: Dudly, ME institute: NIBR contributor address: Surgery Branch, National Cancer Institute, National Institutes of Health PaulRobbins@mail.nih.govSurgery ranch, Center for Cancer Research, National Cancer Institute,National Institutes of HealthSurgery, University of California, IrvineSurgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of HealthSurgery ranch, Center for Cancer Research, National Cancer Institute,National Institutes of HealthSurgery ranch, Center for Cancer Research, National Cancer Institute,National Institutes of HealthNational Cancer Institute, Surgery Branch, NCIInstitute for Biomedical Research, Novartis PharmaceuticalsSurgery Branch, National Cancer Institute, National Institutes of HealthSurgery Branch, National Cancer Institute, NIHSurgery Branch, National Cancer InstituteSurgery Branch, National Cancer InstituteSurgery Branch, Center for Cancer Research, National Institutes of Health, National Cancer InstituteSurgery Branch, Center for Cancer Research, National Institutes of Health, National Cancer InstituteSurgery Branch, Center for Cancer Research, National Institutes of Health, National Cancer InstituteSurgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of HealthSurgery Branch, National Institutes of HealthSurgery Branch, Center for Cancer Research, National Cancer Institute
Date Deposited:	13 Oct 2015 13:11
Last Modified:	13 Oct 2015 13:11
URI:	https://oak.novartis.com/id/eprint/24917